Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8767 |
High Similarity |
NPD7266 |
Discontinued |
0.8205 |
Intermediate Similarity |
NPD1653 |
Approved |
0.8095 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.8072 |
Intermediate Similarity |
NPD7228 |
Approved |
0.795 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7949 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.787 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7811 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7803 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7765 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7758 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7733 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7719 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7688 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7688 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7674 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7674 |
Intermediate Similarity |
NPD7240 |
Approved |
0.767 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7669 |
Intermediate Similarity |
NPD37 |
Approved |
0.7667 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7647 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7636 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7636 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7636 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7636 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7619 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7616 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7595 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7578 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7529 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7517 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7468 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7456 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7427 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7427 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7427 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7403 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7403 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7371 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7366 |
Intermediate Similarity |
NPD7680 |
Approved |
0.7365 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7353 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.7293 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7278 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7267 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7261 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7248 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7243 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7205 |
Intermediate Similarity |
NPD8166 |
Discontinued |
0.72 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.72 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7143 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7101 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7101 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7078 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7041 |
Intermediate Similarity |
NPD7945 |
Clinical (unspecified phase) |
0.7018 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7012 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7006 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.6995 |
Remote Similarity |
NPD8151 |
Discontinued |
0.6994 |
Remote Similarity |
NPD4628 |
Phase 3 |
0.6966 |
Remote Similarity |
NPD228 |
Approved |
0.6964 |
Remote Similarity |
NPD7458 |
Discontinued |
0.6962 |
Remote Similarity |
NPD3620 |
Phase 2 |
0.6962 |
Remote Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.6961 |
Remote Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.6959 |
Remote Similarity |
NPD3817 |
Phase 2 |
0.6944 |
Remote Similarity |
NPD7549 |
Discontinued |
0.6928 |
Remote Similarity |
NPD2983 |
Phase 2 |
0.6928 |
Remote Similarity |
NPD2982 |
Phase 2 |
0.6923 |
Remote Similarity |
NPD4908 |
Phase 1 |
0.6923 |
Remote Similarity |
NPD1358 |
Approved |
0.6923 |
Remote Similarity |
NPD4380 |
Phase 2 |
0.6919 |
Remote Similarity |
NPD7768 |
Phase 2 |
0.6918 |
Remote Similarity |
NPD230 |
Phase 1 |
0.6914 |
Remote Similarity |
NPD6232 |
Discontinued |
0.6901 |
Remote Similarity |
NPD2801 |
Approved |
0.6901 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.6893 |
Remote Similarity |
NPD7473 |
Discontinued |
0.6879 |
Remote Similarity |
NPD7095 |
Approved |
0.6879 |
Remote Similarity |
NPD7075 |
Discontinued |
0.6867 |
Remote Similarity |
NPD4357 |
Discontinued |
0.6863 |
Remote Similarity |
NPD2981 |
Phase 2 |
0.6859 |
Remote Similarity |
NPD2861 |
Phase 2 |
0.6859 |
Remote Similarity |
NPD9494 |
Approved |
0.6855 |
Remote Similarity |
NPD4060 |
Phase 1 |
0.6854 |
Remote Similarity |
NPD3751 |
Discontinued |
0.6836 |
Remote Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.6835 |
Remote Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.6835 |
Remote Similarity |
NPD6798 |
Discontinued |
0.6829 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.6826 |
Remote Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.6823 |
Remote Similarity |
NPD7435 |
Discontinued |
0.6818 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6813 |
Remote Similarity |
NPD4340 |
Discontinued |
0.6813 |
Remote Similarity |
NPD1933 |
Approved |
0.6807 |
Remote Similarity |
NPD6783 |
Clinical (unspecified phase) |
0.6796 |
Remote Similarity |
NPD7038 |
Approved |
0.6796 |
Remote Similarity |
NPD7039 |
Approved |
0.677 |
Remote Similarity |
NPD2492 |
Phase 1 |
0.677 |
Remote Similarity |
NPD6653 |
Approved |
0.6763 |
Remote Similarity |
NPD5402 |
Approved |
0.6757 |
Remote Similarity |
NPD5283 |
Phase 1 |
0.6752 |
Remote Similarity |
NPD3018 |
Phase 2 |
0.6736 |
Remote Similarity |
NPD3134 |
Approved |
0.673 |
Remote Similarity |
NPD3764 |
Approved |
0.6727 |
Remote Similarity |
NPD4237 |
Approved |
0.6727 |
Remote Similarity |
NPD4236 |
Phase 3 |
0.6727 |
Remote Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.6725 |
Remote Similarity |
NPD7028 |
Phase 2 |
0.6708 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6708 |
Remote Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.6708 |
Remote Similarity |
NPD5124 |
Phase 1 |
0.6707 |
Remote Similarity |
NPD5762 |
Approved |
0.6707 |
Remote Similarity |
NPD5763 |
Approved |
0.6706 |
Remote Similarity |
NPD3687 |
Approved |
0.6706 |
Remote Similarity |
NPD3686 |
Approved |
0.6705 |
Remote Similarity |
NPD7819 |
Suspended |
0.6705 |
Remote Similarity |
NPD5563 |
Clinical (unspecified phase) |
0.6705 |
Remote Similarity |
NPD5494 |
Approved |
0.6705 |
Remote Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.6705 |
Remote Similarity |
NPD6818 |
Clinical (unspecified phase) |
0.6701 |
Remote Similarity |
NPD7874 |
Approved |
0.6701 |
Remote Similarity |
NPD7870 |
Phase 2 |
0.6701 |
Remote Similarity |
NPD7875 |
Clinical (unspecified phase) |
0.6701 |
Remote Similarity |
NPD7871 |
Phase 2 |
0.6689 |
Remote Similarity |
NPD7843 |
Approved |
0.6687 |
Remote Similarity |
NPD4110 |
Phase 3 |
0.6687 |
Remote Similarity |
NPD5588 |
Approved |
0.6687 |
Remote Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.6686 |
Remote Similarity |
NPD6273 |
Approved |
0.6686 |
Remote Similarity |
NPD6386 |
Approved |
0.6686 |
Remote Similarity |
NPD7411 |
Suspended |
0.6686 |
Remote Similarity |
NPD6385 |
Approved |
0.6686 |
Remote Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.6684 |
Remote Similarity |
NPD6823 |
Phase 2 |
0.6667 |
Remote Similarity |
NPD6777 |
Approved |
0.6667 |
Remote Similarity |
NPD7783 |
Phase 2 |
0.6667 |
Remote Similarity |
NPD6781 |
Approved |
0.6667 |
Remote Similarity |
NPD6780 |
Approved |
0.6667 |
Remote Similarity |
NPD7782 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD6841 |
Approved |
0.6667 |
Remote Similarity |
NPD6779 |
Approved |
0.6667 |
Remote Similarity |
NPD6776 |
Approved |
0.6667 |
Remote Similarity |
NPD1511 |
Approved |
0.6667 |
Remote Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD6959 |
Discontinued |
0.6667 |
Remote Similarity |
NPD5125 |
Phase 3 |
0.6667 |
Remote Similarity |
NPD6843 |
Phase 3 |
0.6667 |
Remote Similarity |
NPD6782 |
Approved |
0.6667 |
Remote Similarity |
NPD6778 |
Approved |
0.6667 |
Remote Similarity |
NPD5126 |
Approved |
0.6667 |
Remote Similarity |
NPD6842 |
Approved |
0.6649 |
Remote Similarity |
NPD7698 |
Approved |
0.6649 |
Remote Similarity |
NPD7696 |
Phase 3 |
0.6649 |
Remote Similarity |
NPD7697 |
Approved |
0.6647 |
Remote Similarity |
NPD5403 |
Approved |
0.6646 |
Remote Similarity |
NPD1558 |
Phase 1 |
0.6646 |
Remote Similarity |
NPD4140 |
Approved |
0.6646 |
Remote Similarity |
NPD2935 |
Discontinued |
0.6627 |
Remote Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.6627 |
Remote Similarity |
NPD3060 |
Approved |
0.6626 |
Remote Similarity |
NPD4536 |
Approved |
0.6626 |
Remote Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.6626 |
Remote Similarity |
NPD4538 |
Approved |
0.6626 |
Remote Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.6625 |
Remote Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.6623 |
Remote Similarity |
NPD3496 |
Discontinued |
0.6622 |
Remote Similarity |
NPD969 |
Suspended |
0.6613 |
Remote Similarity |
NPD8434 |
Phase 2 |
0.6605 |
Remote Similarity |
NPD447 |
Suspended |
0.6599 |
Remote Similarity |
NPD7701 |
Phase 2 |
0.6595 |
Remote Similarity |
NPD8054 |
Approved |
0.6595 |
Remote Similarity |
NPD8053 |
Approved |
0.6588 |
Remote Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.6588 |
Remote Similarity |
NPD1512 |
Approved |
0.6585 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6581 |
Remote Similarity |
NPD422 |
Phase 1 |
0.6578 |
Remote Similarity |
NPD7906 |
Approved |
0.6577 |
Remote Similarity |
NPD5535 |
Approved |
0.6571 |
Remote Similarity |
NPD5353 |
Approved |
0.657 |
Remote Similarity |
NPD3455 |
Phase 2 |
0.657 |
Remote Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.6561 |
Remote Similarity |
NPD3225 |
Approved |
0.6556 |
Remote Similarity |
NPD7157 |
Approved |
0.6552 |
Remote Similarity |
NPD6801 |
Discontinued |
0.6531 |
Remote Similarity |
NPD8319 |
Approved |
0.6531 |
Remote Similarity |
NPD8320 |
Phase 1 |
0.6529 |
Remote Similarity |
NPD4160 |
Clinical (unspecified phase) |
0.6529 |
Remote Similarity |
NPD5401 |
Approved |
0.6529 |
Remote Similarity |
NPD7446 |
Clinical (unspecified phase) |
0.6524 |
Remote Similarity |
NPD8150 |
Discontinued |
0.6514 |
Remote Similarity |
NPD5773 |
Approved |
0.6514 |
Remote Similarity |
NPD5772 |
Approved |
0.6506 |
Remote Similarity |
NPD1375 |
Discontinued |
0.6506 |
Remote Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.6503
|
Remote Similarity |
NPD5735 |
Approved |